Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction where shares were converted into $41.00 cash plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Common stock shareholders received $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding stock options and restricted stock units (RSUs) were either converted into cash and CVRs or cancelled based on their exercise price relative to the offer terms.
• Apellis Pharmaceuticals is now a wholly owned subsidiary of Biogen.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral-to-positive event for shareholders, as the acquisition provides a definitive exit at a premium, though the CVR component introduces speculative future value.

Positives

• Shareholders received a defined cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share if specific milestones are met.
• Performance-based RSU awards were settled at 200% of target based on relative total shareholder return performance.

Negatives

• Stock options with an exercise price of $45.00 or greater were cancelled without any consideration.
• The acquisition results in the delisting of Apellis Pharmaceuticals as an independent public entity.

Risks

• The $4.00 per share CVR payment is contingent upon the achievement of specific milestones, which may not be realized.
• The CVRs are non-transferable, limiting liquidity for holders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Biogen; future operations will be integrated into the parent company's structure.

Management Comments

• The compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, resulting in a 200% payout for applicable RSU awards.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies acquiring mid-cap innovators to bolster their pipelines, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• The use of CVRs in this transaction is consistent with recent biopharma M&A trends where future clinical or regulatory milestones are uncertain.
• The cash-plus-CVR structure is a standard mechanism used to bridge valuation gaps between acquirers and target boards.

Stakeholder Impact

• Shareholders receive cash consideration for their equity.
• Employees and management transition to a subsidiary structure under Biogen.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, Tender Offer